Skip to content

Posterior capsule opacification

TL;DR — PCO is the commonest long-term complication of cataract surgery: residual lens epithelial cells (LECs) proliferate, migrate onto the posterior capsule and undergo epithelial–mesenchymal transition, scattering light and reducing acuity and contrast (Wormstone 2021, PMID 32977000). Pooled incidence in the pre-sharp-edge era was 11.8% (95% CI 9.3–14.3) at 1 year, 20.7% (16.6–24.9) at 3 years and 28.4% (18.4–38.4) at 5 years (Schaumberg 1998, PMID 9663224). The single most effective countermeasure is a sharp posterior optic edge: Cochrane analysis found Nd:YAG capsulotomy RR 0.21 (95% CI 0.11–0.41) at three years and 0.21 (0.10–0.45) at five, corresponding to 170 and 331 fewer capsulotomies per 1,000 eyes (Maedel 2021, PMID 34398965). Material matters less than edge design — an earlier Cochrane review of 66 studies found sharp edges lowered PCO score by 8.65 points on a 0–100 scale and Nd:YAG rate to 0.19 (0.11–0.35), with no clear difference between optic materials (Findl 2010, PMID 20166069). Nd:YAG capsulotomy is effective but not free: symptomatic IOL damage requiring explantation was identified in up to 9.3% of retrospectively analysed cases in one systematic review of laser-induced lens damage (Borkenstein 2025, PMID 40862048).

What PCO is, and what endpoint is being measured

A modern cataract operation leaves a capsular bag consisting of a rim of anterior capsule and the entire posterior capsule. Lens epithelial cells remain attached to the anterior capsule; in response to surgical trauma they mount a wound-healing response, re-colonise the denuded anterior capsule, encroach onto the IOL surface and colonise the posterior capsule (Wormstone 2009, PMID 19013456; PMID 32977000). Two clinically distinct forms are described: fibrotic PCO, following classical fibrotic processes with hyperproliferation and matrix deposition, and regenerative PCO, in which residual cells form Elschnig pearls and Soemmering's ring (PMID 32977000). Delayed-onset PCO occurring years after surgery without obvious inflammation implicates a third mechanism — LEC senescence with a senescence-associated secretory phenotype driving EMT; in rabbit PCO models and oxidative-stress-induced senescent SRA01/04 cells, dasatinib plus quercetin targeted senescent cells and inhibited the SASP (Ma 2025, PMID 40660668). The molecular literature adds oxidative stress and extracellular-matrix remodelling to proliferation, migration and EMT as the core processes (Wang 2025, PMID 40825390; Konopińska 2021, PMID 34199147).

Three different endpoints appear in the literature and must not be interchanged:

Endpoint What it measures Bias
Any PCO on retroillumination Presence of cells on the capsule Insensitive to visual significance; 29.93% at 3 months in one 1,039-eye cohort (Gu 2022, PMID 34727350)
PCO score (AQUA, EPCO) Graded severity of opacification Not pooled across studies because of reporting differences (PMID 34398965)
Nd:YAG capsulotomy rate A treatment decision Depends on threshold, access, reimbursement and follow-up duration

Objective quantification is improving: swept-source OCT posterior capsule thickness (mean 8.0 ± 2.7 vs 5.0 ± 0.9 pixel units in lasered vs control eyes; sensitivity 85%, specificity 74%, AUC 0.942) and Scheimpflug grey value (91%, 76%, AUC 0.947) both discriminate well in 162 eyes (Zhou 2023, PMID 37407917). AI models report AUC up to 0.97 for binary detection of vision-threatening PCO, r ≈ 0.83 for continuous severity, and C-index ≈ 0.87 for capsulotomy-risk nomograms, but the named barriers are large multi-centre datasets, prospective validation, regulatory approval and EHR integration (Gill 2025, PMID 41458487).

Incidence

Estimate Value Population Source
Pooled PCO at 1 / 3 / 5 years 11.8% (9.3–14.3) / 20.7% (16.6–24.9) / 28.4% (18.4–38.4) Meta-analysis of ECCE and phacoemulsification with posterior-chamber IOL; significant heterogeneity, no decline over the study period Schaumberg 1998, PMID 9663224
Any early PCO at 3 months 29.93% 1,039 eyes after uneventful phaco+IOL Gu 2022, PMID 34727350
Grade 3–4 early PCO at 3 months 2.98% (31 patients) same PMID 34727350
Contemporary narrative estimate ≈30% incidence Review Milazzo 2014, PMID 25455552
Modern experimental-study review estimate Can be as high as 10% Review Konopińska 2021, PMID 34199147
Affected within 5 years Up to one-fifth of patients AI review Gill 2025, PMID 41458487
Nd:YAG at 12 months, capsulotomy-fixated vs in-the-bag IOL of identical material and optic 3.1% vs 4.7% Systematic review Beckers 2025, PMID 41096027

The spread across these figures — 10% to 30% — is almost entirely definitional plus era and follow-up duration, and is the reason the field's own reviews warn against treating PCO incidence, visually significant PCO and Nd:YAG rate as one quantity.

Modifiable factors

IOL optic edge

Follow-up Effect of sharp vs round edge Eyes / studies Certainty Source
1 year Peto OR 0.30 (95% CI 0.05–1.74); 1/371 vs 4/371 capsulotomies; ≈7 fewer per 1,000 (9 fewer to 7 more) 742 eyes, 6 studies Low Maedel 2021, PMID 34398965
2 years RR 0.35 (0.16–0.80); 89 fewer per 1,000 703 eyes, 6 studies — PMID 34398965
3 years RR 0.21 (0.11–0.41); 170 fewer per 1,000 538 eyes, 6 studies — PMID 34398965
5 years RR 0.21 (0.10–0.45); 331 fewer per 1,000 306 eyes, 4 studies — PMID 34398965
PCO score Consistently lower with sharp edges by ~0.5–3 units in all 10 studies 1,065 people, 1,834 eyes Moderate PMID 34398965
Pooled (older review) PCO score −8.65 (−10.72 to −6.59) on 0–100 scale; Nd:YAG rate 0.19 (0.11–0.35) 66 studies — Findl 2010, PMID 20166069

The one-year estimate is imprecise simply because capsulotomy events are rare early; the effect is measured precisely only once events accumulate (PMID 34398965). The mechanism is the capsular bend: a sharp posterior edge creates a discontinuity that contact-inhibits migrating LECs, and a three-piece IOL allows a full 360° bend around the optic edge while some single-piece designs may inhibit its formation (Dewey 2006, PMID 16436924; Nishi 1999, PMID 9888086).

IOL material

Material effects are real but smaller and inconsistent. The 66-study Cochrane review found no significant difference between PMMA, hydrogel, hydrophobic acrylic and silicone, though hydrogel tended to higher and silicone to lower PCO scores (PMID 20166069). An earlier meta-analysis of 23 RCTs found pooled risk differences in Nd:YAG rate of −24% (95% CI −29% to −20%) for acrylic versus PMMA, −9% (−17% to −1%) for silicone versus PMMA, +19% (8% to 30%) for hydrogel versus acrylic and +28% (10% to 46%) for hydrogel versus silicone, with no significant difference between silicone and acrylic (4%, −2% to 10%) (Cheng 2007, PMID 17224119). Hydrophilic acrylic lenses are more susceptible than hydrophobic to both calcification and PCO, and their use is specifically discouraged where vitrectomy, endothelial keratoplasty or intraocular gas is likely (Grzybowski 2022, PMID 34843687; Tripodi 2023, PMID 36866563). Biocompatibility has two separable axes — uveal (inflammatory foreign-body reaction) and capsular (LEC behaviour) — and lenses implanted early in life are expected to perform for decades (Özyol 2017, PMID 28845327).

Surgical factors

Capsulorhexis–IOL overlap is the surgeon-controlled variable with the clearest quantitative signal. In 1,039 eyes, incomplete overlap raised early PCO risk (180–360° overlap OR 2.058, P < 0.001; <180° overlap OR 5.403, P < 0.001), and previous pars plana vitrectomy was an independent risk factor (OR 2.664, P = 0.003) (PMID 34727350). Capsulotomy-fixated IOLs, which force close capsule–optic contact, showed lower Nd:YAG rates than in-the-bag lenses of identical material and optic design (3.1% vs 4.7% at 12 months) — early evidence that anterior fixation may reduce the potential space for LEC migration, limited by study heterogeneity and short follow-up (PMID 41096027).

Drugs

The randomised evidence for pharmacological prevention is negative except for one experimental agent: across 66 studies, no difference was found between types of intra- or postoperative anti-inflammatory treatment, except that an immunotoxin (MDX-A) significantly lowered PCO rate (PMID 20166069). Experimental approaches — an immunotoxin specific for human LECs, b-FGF-saporin, EDTA and RGD peptides, and capsular tension rings as mechanical barriers — have been explored for decades without a licensed product (PMID 9888086; Clark 2000, PMID 10724829).

Observational data suggest that postoperative steroid choice may matter after all. In a retrospective registry analysis of 13,368 analysed patients (from 25,818 consecutive operations, mean follow-up 22.8 ± 15.7 months), steroid monotherapy was associated with significantly lower Nd:YAG capsulotomy rates than NSAID monotherapy, and this persisted after adjustment for age, sex, pseudoexfoliation and risk stratification (HR 0.70, 95% CI 0.52–0.88, P = .001); combination steroid plus NSAID conferred no added benefit over steroid alone (HR 1.11, 0.68–1.80, P = .674) (Hecht 2020, PMID 32061757). This conflicts with the randomised Cochrane conclusion, and the discordance is unresolved. Comment literature on pharmacological "secondary cataract prevention" reflects the same long-standing uncertainty (Rabsilber 2007, PMID 17270697; Bellini 2008, PMID 18166414).

Nd:YAG capsulotomy and its costs

Nd:YAG laser capsulotomy is the standard treatment for visually significant PCO and is quick and non-invasive, but the procedure carries real risks: transient IOP spikes, cystoid macular oedema, rare retinal detachment, and damage to the IOL itself (PMID 25455552; PMID 41458487). A systematic review of 53 publications on laser-induced IOL damage found morphological changes from superficial micro-pits to crater formation and delamination — particularly prominent in hydrophobic acrylic and small-aperture (pinhole) IOLs — with measurable optical degradation (reduced contrast sensitivity, increased glare, higher-order aberrations) after central pit formation, and symptomatic damage requiring explantation identified in up to 9.3% of retrospectively analysed cases. Effective preventive measures were peripheral laser patterns, posterior offset focusing, minimal effective energy (<1.8 mJ) and structured alignment; robust clinical data linking experimental findings to patient outcomes were described as scarce (PMID 40862048). Capsulotomy is also a significant financial burden on health systems worldwide (PMID 34398965).

Not every fall in vision after surgery is PCO; the differential includes macular disease, IOL opacification, capsular contraction and refractive change (Gaonker 2023, PMID 35245234; Hodge 1998, PMID 9627636). In diabetes, Nd:YAG capsulotomy has been examined as a potential trigger for retinopathy progression (Alshaikhsalama 2026, PMID 41719525).

Special populations

  • Children. Visual axis opacification is the commonest complication of paediatric cataract surgery, which is why primary posterior capsulorhexis with anterior vitrectomy is standard in young children (Zetterström 2007, PMID 17944624; Knebel 2026, PMID 42285159). In the TAPS bilateral 7–24-month cohort, recurrent visual-axis opacification occurred in 7.5% and was associated only with IOL use (OR 6.10, P = 0.005) (Bothun 2021, PMID 32679160). Premium optics in children remain unproven (Asif 2023, PMID 36124376).
  • Previous vitrectomy. Independent risk factor for early PCO (OR 2.664) (PMID 34727350); primary posterior continuous curvilinear capsulorhexis has been proposed for these eyes (PMID 34727350).
  • Retinitis pigmentosa. PCO occurred in 82.5% of 80 operated eyes and 52.5% underwent Nd:YAG at a mean of 10.8 months (Dikopf 2013, PMID 23628349).
  • Diabetes. PCO is listed among the vision-threatening postoperative risks in diabetic eyes (Kiziltoprak 2019, PMID 30891150).

Open questions

  • Do steroids reduce PCO? A 13,368-patient registry analysis found lower capsulotomy rates with steroid than NSAID monotherapy after adjustment (HR 0.70, 0.52–0.88) (PMID 32061757), while the randomised Cochrane synthesis of 66 studies found no effect of anti-inflammatory regimen (PMID 20166069). No randomised trial has tested steroid versus NSAID with capsulotomy as a prespecified endpoint.
  • Can PCO risk be predicted well enough to individualise follow-up? AI capsulotomy-risk nomograms report C-index ≈ 0.87 (PMID 41458487), but no model has been prospectively validated or shown to change follow-up scheduling or outcomes.
  • Does capsulotomy fixation reduce PCO? The FEMTIS-versus-in-the-bag comparison is a systematic review of heterogeneous studies with short follow-up (PMID 41096027); no randomised trial with ≥3-year Nd:YAG rates was identified in this session's searches.
  • How often does Nd:YAG damage matter clinically? Up to 9.3% symptomatic IOL damage requiring explantation was found in retrospective series, and the review explicitly states that robust clinical data linking laboratory findings to patient outcomes are scarce, calling for large prospective studies especially in premium IOLs (PMID 40862048).
  • Are senolytics a plausible PCO therapy? Dasatinib plus quercetin inhibited SASP and EMT in rabbit models and senescent human LECs (PMID 40660668); no human study exists.
  • What is contemporary PCO incidence? The pooled 1/3/5-year figures date from 1998 and predate universal sharp-edge design (PMID 9663224); no updated meta-analysis restricted to modern sharp-edged hydrophobic IOLs was identified in this session's searches.

References

  1. Wormstone IM, Wormstone YM, Smith AJO, et al. Posterior capsule opacification: What's in the bag?. Progress in retinal and eye research. 2021;82:100905. PMID 32977000
  2. Schaumberg DA, Dana MR, Christen WG, et al. A systematic overview of the incidence of posterior capsule opacification. Ophthalmology. 1998;105:1213-21. PMID 9663224
  3. Maedel S, Evans JR, Harrer-Seely A, et al. Intraocular lens optic edge design for the prevention of posterior capsule opacification after cataract surgery. The Cochrane database of systematic reviews. 2021;8:CD012516. PMID 34398965
  4. Findl O, Buehl W, Bauer P, et al. Interventions for preventing posterior capsule opacification. The Cochrane database of systematic reviews. 2010;2010:CD003738. PMID 20166069
  5. Borkenstein AF, Borkenstein EM. Neodymium-Doped Yttrium Aluminum Garnet (Nd:YAG) Laser-Induced Damage to Intraocular Lenses: A Systematic Review of Mechanisms, Clinical Consequences, and Preventive Strategies. Cureus. 2025;17:e90903. PMID 40862048
  6. Wormstone IM, Wang L, Liu CS. Posterior capsule opacification. Experimental eye research. 2009;88:257-69. PMID 19013456
  7. Ma Y, Ren Z, Chen Y, et al. Novel Insight of Posterior Capsule Opacification: The Role of Lens Epithelial Cell Senescence. Clinical & experimental ophthalmology. 2025;53:1008-1024. PMID 40660668
  8. Wang Y, Cao K, Li M, et al. Posterior capsular Opacification: Pathogenesis, challenges, and innovative therapeutic strategies. Experimental eye research. 2025;259:110585. PMID 40825390
  9. Konopińska J, Młynarczyk M, Dmuchowska DA, et al. Posterior Capsule Opacification: A Review of Experimental Studies. Journal of clinical medicine. 2021;10. PMID 34199147
  10. Gu X, Chen X, Jin G, et al. Early-Onset Posterior Capsule Opacification: Incidence, Severity, and Risk Factors. Ophthalmology and therapy. 2022;11:113-123. PMID 34727350
  11. Zhou Y, Xiang J, Xu F, et al. Objective quantification of posterior capsule opacification after cataract surgery with swept-source optical coherence tomography. BMC ophthalmology. 2023;23:299. PMID 37407917
  12. Gill G, Taylor Gonzalez D, Sanghvi H, et al. Artificial intelligence for posterior capsule opacification. Frontiers in medicine. 2025;12:1695525. PMID 41458487
  13. Milazzo S, Grenot M, Benzerroug M. [Posterior capsule opacification]. Journal francais d'ophtalmologie. 2014;37:825-30. PMID 25455552
  14. Beckers D, Kretz F, Mehta J, et al. Analyzing the Relationship Between IOL Fixation and PCO Prevention. Journal of clinical medicine. 2025;14. PMID 41096027
  15. Dewey S. Posterior capsule opacification. Current opinion in ophthalmology. 2006;17:45-53. PMID 16436924
  16. Nishi O. Posterior capsule opacification. Part 1: Experimental investigations. Journal of cataract and refractive surgery. 1999;25:106-17. PMID 9888086
  17. Cheng JW, Wei RL, Cai JP, et al. Efficacy of different intraocular lens materials and optic edge designs in preventing posterior capsular opacification: a meta-analysis. American journal of ophthalmology. 2007;143:428-36. PMID 17224119
  18. Grzybowski A, Zemaitiene R, Markeviciute A, et al. Should We Abandon Hydrophilic Intraocular Lenses?. American journal of ophthalmology. 2022;237:139-145. PMID 34843687
  19. Tripodi S, Toro MD, Rejdak R, et al. Qualitative and quantitative analysis of an explanted opacified hydrophilic IOL after over two years from cataract surgery. European journal of ophthalmology. 2023;33:NP28-NP34. PMID 36866563
  20. Özyol P, Özyol E, Karel F. Biocompatibility of Intraocular Lenses. Turkish journal of ophthalmology. 2017;47:221-225. PMID 28845327
  21. Clark DS. Posterior capsule opacification. Current opinion in ophthalmology. 2000;11:56-64. PMID 10724829
  22. Hecht I, Karesvuo P, Achiron A, et al. Anti-inflammatory Medication After Cataract Surgery and Posterior Capsular Opacification. American journal of ophthalmology. 2020;215:104-111. PMID 32061757
  23. Rabsilber TM, Limberger IJ, Reuland AJ, et al. Secondary cataract prevention. Ophthalmology. 2007;114:397-8. PMID 17270697
  24. Bellini LP, Brum GS. Secondary cataract prevention. Ophthalmology. 2008;115:212; author reply 212-3. PMID 18166414
  25. Gaonker T, Yadav A, Nishad A. Post-Cataract Surgery Decreased Vision-Is It Always Posterior Capsule Opacification?. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2023;12:107. PMID 35245234
  26. Hodge WG. Posterior capsule opacification after cataract surgery. Ophthalmology. 1998;105:943-4. PMID 9627636
  27. Alshaikhsalama AM, Mansoor BS, Zaidi Z, et al. Risk of diabetic retinopathy progression after YAG laser capsulotomy. Journal of cataract and refractive surgery. 2026;52:282-288. PMID 41719525
  28. Zetterström C, Kugelberg M. Paediatric cataract surgery. Acta ophthalmologica Scandinavica. 2007;85:698-710. PMID 17944624
  29. Knebel D, Ehrt O. [Childhood cataract]. Klinische Monatsblatter fur Augenheilkunde. 2026. PMID 42285159
  30. Bothun ED, Wilson ME, Yen KG, et al. Outcomes of Bilateral Cataract Surgery in Infants 7 to 24 Months of Age Using the Toddler Aphakia and Pseudophakia Treatment Study Registry. Ophthalmology. 2021;128:302-308. PMID 32679160
  31. Asif MI, Raj N, Kalra N, et al. Premium intraocular lenses in children. European journal of ophthalmology. 2023;33:1517-1528. PMID 36124376
  32. Dikopf MS, Chow CC, Mieler WF, et al. Cataract extraction outcomes and the prevalence of zonular insufficiency in retinitis pigmentosa. American journal of ophthalmology. 2013;156:82-88.e2. PMID 23628349
  33. Kiziltoprak H, Tekin K, Inanc M, et al. Cataract in diabetes mellitus. World journal of diabetes. 2019;10:140-153. PMID 30891150